学科与关键词
关键词
third-generation EGFR-TKIbefotertinibT790M
- Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyLu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jian, Hong; Chen, Chengshui; Jin, Xiangming; Tian, Panwen; Wang, Kai; Jiang, Guanming; Chen, Gongyan; Chen, Qun; Zhao, Hui; Ding, Cuimin; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Liu, Zhe; Fang, Jian; Yang, Junquan; Zhuang, Wu; Liu, Yunpeng; Zhang, Jian; Pan, Yueyin; Chen, Jun; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, YanJournal of Thoracic Oncology, 2022, 17(10): 1192-1204.被引 7
- Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)Lu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Ding, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyLu, Shun*; Zhou, Jianying*; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, PingLancet Respiratory Medicine, 2023, 11(10): 905-915.被引 6
